Stock comparison
Haleon
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HLN
Haleon
Market cap
$41.25B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HLN | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 54D | 77B | LMAT |
| Benjamin Graham | 55C | 89A | LMAT |
| Philip Fisher | 49D | 81C | LMAT |
| Peter Lynch | 54C | 67B | LMAT |
| Joel Greenblatt | 49D | 56D | LMAT |
| Charlie Munger | 47D | 68D | LMAT |
| Terry Smith | 43D | 69D | LMAT |
Side-by-side metrics
| Metric | HLN | LMAT |
|---|---|---|
| Market cap | $41.25B | $2.23B |
| P/E (TTM) | 28.8x | 37.1x |
| EV/EBIT | 35.6x | 36.6x |
| ROIC (TTM) | 4.13% | 9.43% |
| Gross margin | 61.45% | 72.39% |
| Net margin | 12.59% | 24.35% |
| Revenue CAGR 5y | 3.11% | 12.75% |
| EPS CAGR 5y | 4.66% | 19.04% |
| Debt / Equity | 0.5x | 0.5x |
| Dividend yield | 2.15% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HLN leads on
- Market cap$41.25Bvs $2.23B+95%
- Dividend yield2.15%vs 0.84%+61%
- P/E (TTM)28.8xvs 37.1x+22%
LMAT leads on
- Revenue CAGR 5y12.75%vs 3.11%+76%
- EPS CAGR 5y19.04%vs 4.66%+76%
- ROIC (TTM)9.43%vs 4.13%+56%
- Net margin24.35%vs 12.59%+48%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.